Analogic Corporation

Analogic — Merger or Acquisition (May 2018)

15 slides from Analogic's merger presentation, May 16, 2018

  1. Slide 1: Analogic Acquisition by Altaris Capital Partners

    May 16, 2018 ANALOGIC ACQUISITION BY ALTARIS CAPITAL PARTNERS

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Statements in this presentation regarding the proposed transaction between Altaris Capital Partners, LLC (including affiliated entities, “Altaris”) and Analogic, the expected timetable for completing the transaction, future financial and operating results, benefits and syn

  3. Slide 3: Altaris Acquisition: Attractive Value and Certainty

    Altaris Acquisition: Attractive Value and Certainty Per Share Offer $84.00 per share, 100% cash Transaction Value Approximately $1.1 billion, on a fully diluted basis Premium 25% premium to Analogic’s closing share price of $67.45 on June 7, 2017, the day after the Company reported quarterly earning

  4. Slide 4: Focused on Providing Maximum Value for Analogic Shareholders

    Focused on Providing Maximum Value for Analogic Shareholders Altaris transaction at $84 per share in cash presents best combination of certainty and value for stockholders Extensive public sale process with direct outreach to potential financial and strategic buyers as well as responses to inbound e

  5. Slide 5: Catalysts for Strategic Review Process

    Larger and better capitalized competitors Long-term macroeconomic trends in medical imaging Need for continued strategic investments Development of new channels to market Past operating performance and need for greater scale Increasing global competition Catalysts for Strategic Review Process Intern

  6. Slide 6: Range of Alternatives Considered

    Sale of Entire Company Range of Alternatives Considered Separating Businesses Immediate and substantial value for all shareholders; Board unanimously recommends transaction Tax leakage and stranded costs; execution risk Continued Operation on Standalone Basis—Short- and Long-term Need for greater sc

  7. Slide 7: Standalone Business Case Review

    Standalone Business Case Review Execution Risk - The Board reviewed the Company’s prospects on a standalone basis and had significant concerns regarding the Company’s ability to deliver the implied value of its operating plan. Past Financial Results - The fiscal 2013-2017 financial results reflected

  8. Slide 8: Wall Street Analyst Expectations Illustrate Ongoing Risk

    Wall Street Analyst Expectations Illustrate Ongoing Risk Analyst model estimates based on Company guidance shows consistently lower expected sequential performance every fiscal year since peak of FY13 EBITDA Estimates Over Time ($ in Millions) Source:FactSet. Market data as of 4/9/2018. Note:Represe

  9. Slide 9: Company's Standalone Financial Projections Present Ongoing Execution Risk

    Company’s Standalone Financial Projections Present Ongoing Execution Risk Implies turnaround in CT, despite slow market growth and challenging competitive market dynamics Assumes significant growth opportunities in Security and Detection business Assumes the Company maintains its Ultrasound market p

  10. Slide 10: Sale of Company Process Overview

    Sale of Company Process Overview Following the Company’s public announcement of a sale process in September 2017 Citi engaged with 75 potential buyers, consisting of 33 strategics and 42 financial sponsors management presentations $84/share, 100% cash offer is most attractive combination of value an

  11. Slide 11: Altaris Transaction Presents Most Attractive Alternative

    Altaris Transaction Presents Most Attractive Alternative Bidder Round 1 Round 2 Updated Bid Final Bid Summary Altaris $80.00 (100% Cash) $82.50 (100% Cash) $82.50 (100% Cash) $84.00 (100% Cash) Increased, all cash bid Best combination of value and certainty Party D Merger-of-Equals (100% Stock) $85.

  12. Slide 12: 100% Cash Deal with Committed Financing

    100% Cash Deal with Committed Financing Established in 2003 Deep expertise in the medical device and diagnostic equipment industries, including imaging technologies Analogic would represent 17th platform company to design and manufacture high value, FDA-regulated medical products and components Inve

  13. Slide 13: Summary

    Summary Altaris acquisition at $84 per share in cash represents the most attractive combination of value and certainty for shareholders Conclusion supported by fairness opinion provided the Board’s financial advisor(1) and analysis of multiple bids Transaction provides shareholders with immediate an

  14. Slide 14: Important Additional Information

    Important Additional Information Analogic plans to file with the Securities and Exchange Commission (the “SEC”) and mail to its stockholders a Proxy Statement in connection with the transaction. The Proxy Statement contains important information about Altaris, Analogic, the transaction and related m

  15. Slide 15: Analogic

    analogic |

Analogic — Merger or Acquisition (May 2018) on 6ix